


Halofuginone hydrobromide

ALTERNATE NAME: (2R*,3S*)-7-Bromo-6-chloro-3-[3-(3-hydroxy-2-piperidiny)-2-oxopropyl]-4-3H-quinazolinone hydrobromide
RU-19110

CATALOG #: B2610-10 10 mg
B2610-50 50 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₆H₁₇BrClN₃O₃·HBr

MOLECULAR WEIGHT: 495.59

CAS NUMBER: 64924-67-0

APPEARANCE: White solid

PURITY: ≥98%

SOLUBILITY: >45 mg/ml DMSO

DESCRIPTION: Halofuginone is an ATP-dependent inhibitor prolyl-tRNA synthetase (K_i of 18.3 nM). Halofuginone attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Blocks expression of MMP2 and inhibits ECM invasion in vitro and lung metastasis by bladder cancer cells in mice. Also inhibits the development of Th17-driven autoimmunity in a mouse model of multiple sclerosis by activating the amino acid response (AAR) pathway.

STORAGE TEMPERATURE: -20°C. Protect from moisture

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

MMP-2, human recombinant (7782)
MMP-2 Antibody (5562R)
MMP-2 Inhibitor Screening Kit (Fluorometric) (K2017)
NSC 405020 (2682)
Disulfiram (2308)
MMP-2 Antibody (5562)

DISCLAIMER: *FOR RESEARCH USE ONLY! Not to be used on humans.*